SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019.

GBD 2019 HIV Collaborators (2021) Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990-2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. Lancet HIV, 8 (10). e633-e651. ISSN 2352-3018 https://doi.org/10.1016/S2352-3018(21)00152-1
SGUL Authors: Pollok, Richard Charles G

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview
[img]
Preview
PDF (Supplementary appendix) Published Version
Available under License Creative Commons Attribution.

Download (6MB) | Preview

Abstract

BACKGROUND: The sustainable development goals (SDGs) aim to end HIV/AIDS as a public health threat by 2030. Understanding the current state of the HIV epidemic and its change over time is essential to this effort. This study assesses the current sex-specific HIV burden in 204 countries and territories and measures progress in the control of the epidemic. METHODS: To estimate age-specific and sex-specific trends in 48 of 204 countries, we extended the Estimation and Projection Package Age-Sex Model to also implement the spectrum paediatric model. We used this model in cases where age and sex specific HIV-seroprevalence surveys and antenatal care-clinic sentinel surveillance data were available. For the remaining 156 of 204 locations, we developed a cohort-incidence bias adjustment to derive incidence as a function of cause-of-death data from vital registration systems. The incidence was input to a custom Spectrum model. To assess progress, we measured the percentage change in incident cases and deaths between 2010 and 2019 (threshold >75% decline), the ratio of incident cases to number of people living with HIV (incidence-to-prevalence ratio threshold <0·03), and the ratio of incident cases to deaths (incidence-to-mortality ratio threshold <1·0). FINDINGS: In 2019, there were 36·8 million (95% uncertainty interval [UI] 35·1-38·9) people living with HIV worldwide. There were 0·84 males (95% UI 0·78-0·91) per female living with HIV in 2019, 0·99 male infections (0·91-1·10) for every female infection, and 1·02 male deaths (0·95-1·10) per female death. Global progress in incident cases and deaths between 2010 and 2019 was driven by sub-Saharan Africa (with a 28·52% decrease in incident cases, 95% UI 19·58-35·43, and a 39·66% decrease in deaths, 36·49-42·36). Elsewhere, the incidence remained stable or increased, whereas deaths generally decreased. In 2019, the global incidence-to-prevalence ratio was 0·05 (95% UI 0·05-0·06) and the global incidence-to-mortality ratio was 1·94 (1·76-2·12). No regions met suggested thresholds for progress. INTERPRETATION: Sub-Saharan Africa had both the highest HIV burden and the greatest progress between 1990 and 2019. The number of incident cases and deaths in males and females approached parity in 2019, although there remained more females with HIV than males with HIV. Globally, the HIV epidemic is far from the UNAIDS benchmarks on progress metrics. FUNDING: The Bill & Melinda Gates Foundation, the National Institute of Mental Health of the US National Institutes of Health (NIH), and the National Institute on Aging of the NIH.

Item Type: Article
Additional Information: © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Keywords: GBD 2019 HIV Collaborators
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Lancet HIV
ISSN: 2352-3018
Language: eng
Dates:
DateEvent
October 2021Published
27 September 2021Published Online
29 June 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
K43 TW010716FIC NIH HHSUNSPECIFIED
R01 AI136664NIAID NIH HHSUNSPECIFIED
R21 TW011706FIC NIH HHSUNSPECIFIED
D43 TW010937FIC NIH HHSUNSPECIFIED
R25 TW011217FIC NIH HHSUNSPECIFIED
UL1 TR001881NCATS NIH HHSUNSPECIFIED
NPRP 9-040-3-008Qatar National Research FundUNSPECIFIED
1135991National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
R01DA1104470National Institute on Drug Abusehttp://dx.doi.org/10.13039/100000026
OPP1190661Bill and Melinda Gates Foundationhttp://dx.doi.org/10.13039/100000865
MR/R015600/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
Np:XMUMRF-C6/ITCM/0004Xiamen University MalaysiaUNSPECIFIED
CEX2018-000806-SCentro de Excelencia Severo OchoaUNSPECIFIED
20-18-00307Russian Science FoundationUNSPECIFIED
1R25TW011217-01Fogarty International Centerhttp://dx.doi.org/10.13039/100000061
1R21TW011706-01Fogarty International Centerhttp://dx.doi.org/10.13039/100000061
1D43TW010937-01A1Fogarty International Centerhttp://dx.doi.org/10.13039/100000061
332821690Aga Khan Development NetworkUNSPECIFIED
RIA2016MC-1615LIFE ProjectUNSPECIFIED
1195716National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
PubMed ID: 34592142
Web of Science ID: WOS:000723115600001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/113954
Publisher's version: https://doi.org/10.1016/S2352-3018(21)00152-1

Actions (login required)

Edit Item Edit Item